Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advisors Question Impact of OxyContin Improvements Due To Generics

Executive Summary

Purdue Pharma may be navigating a complicated regulatory path to extending its dominant market position for OxyContin

You may also be interested in...



Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin

Purdue Pharma is looking for assistance from FDA to help protect the company’s OxyContin franchise from both branded and generic competitors.

Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin

Purdue Pharma is looking for assistance from FDA to help protect the company’s OxyContin franchise from both branded and generic competitors.

FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit

Purdue's reformulated OxyContin could face generics in 2013 unless FDA withdraws the initial NDA because of safety concerns.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel